Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 658 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 Mom with Breast Cancer Who Had A Year to Live Goes... April 2, 2019 Coming Soon: Medicare Drug Price Negotiations September 1, 2023 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Load more HOT NEWS Research with Integrity – integrating training into research culture From smouldering ash to a gleaming temple for cancer research: The... Frederick National Laboratory for Cancer Research: A Unique Resource for the... FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer
